Literature DB >> 773733

Inhibition of tumor growth in vivo and in vitro by macrophages from rats treated with a streptococcal preparation, OK-432.

Y Ishii, H Yamaoka, K Toh, K Kikuchi.   

Abstract

The role of macrophages from rats treated with a streptococcal preparation (OK-432) for inhibition of syngeneic tumor growth was examined both in vivo and in vitro. Treatment of rats with OK-432 intraperitoneally resulted in a transient inhibition of ascites tumor growth and concomitant increase in survival time. Peritoneal exudate cells from these rats completely suppressed tumor growth when admixed with tumor cells and transferred subcutaneously to syngeneic recipient rats. No such effect was observed with tumor cells from saline-treated control rats. The macrophages were responsible for the neutralization of tumor growth, since the removal of adherent cells from peritoneal exudate cells of rats treated with OK-432 resulted in the abrogation of their antitumor activity. To further investigate the antitumor activity of macrophages, an in vitro cytotoxicity assay was carried out on several tumor cell lines. A complete target cell destruction was brought about by macrophages from the rats treated with OK-432 but not from the control animals. The tumor cytotoxicity mediated by macrophages activated with OK-432 was regarded as non-specific because they could damage all the target cell lines tested.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 773733

Source DB:  PubMed          Journal:  Gan        ISSN: 0016-450X


  21 in total

1.  Preliminary result of mixed bacterial vaccine as adjuvant treatment of hepatocellular carcinoma.

Authors:  Z Y Tang; H Y Zhou; G Zhao; L M Chai; M Zhou; J Z Lu; K D Liu; H F Havas; H C Nauts
Journal:  Med Oncol Tumor Pharmacother       Date:  1991

2.  Pronounced antitumor effect of LAK-like cells induced in the peritoneal cavity of mice after intraperitoneal injection of OK-432, a killed streptococcal preparation.

Authors:  M Saito; O Ichimura; M Kataoka; Y Moriya; K Ueno; Y Sugawara; M Nanjo; N Ishida
Journal:  Cancer Immunol Immunother       Date:  1986       Impact factor: 6.968

3.  Postoperative adjuvant immunochemotherapy with mitomycin C, tegafur, PSK and/or OK-432 for gastric cancer, with special reference to the change in stimulation index after gastrectomy.

Authors:  T Hattori; T Nakajima; H Nakazato; T Tanabe; K Kikuchi; O Abe; T Kondo; T Taguchi; N Komi; K Sugimachi
Journal:  Jpn J Surg       Date:  1990-03

4.  An adhesive glycoprotein from rat ascites hepatoma cells potentiates natural cytotoxic activity by rat spleen cells.

Authors:  J Y Chen; R Kurano; M Hirashima; H Hayashi
Journal:  Immunology       Date:  1986-05       Impact factor: 7.397

5.  Inhibition of in vitro LAK generation by OK-432.

Authors:  M Yagita; E A Grimm
Journal:  Cancer Immunol Immunother       Date:  1986       Impact factor: 6.968

6.  Augmentation of natural killer (NK) cell activity by a streptococcal preparation, OK-432, in patients with malignant tumors.

Authors:  H Wakasugi; K Oshimi; M Miyata; Y Morioka
Journal:  J Clin Immunol       Date:  1981-07       Impact factor: 8.317

7.  Induction of activated natural killer cells from murine spleen cells primed in vivo and subsequently challenged in vitro with the streptococcal preparation OK432.

Authors:  H Yamaue; M Katsumi; K Tabuse; Y Tabuse; K Kuribayashi; T Nishihara; K Saito
Journal:  Cancer Immunol Immunother       Date:  1987       Impact factor: 6.968

8.  Oxygen radical production by peritoneal macrophages and Kupffer cells elicited with Lactobacillus casei.

Authors:  S Hashimoto; K Nomoto; T Matsuzaki; T Yokokura; M Mutai
Journal:  Infect Immun       Date:  1984-04       Impact factor: 3.441

9.  Studies on the immunopotentiating effects of a streptococcal preparation, OK-432. I. Enhancement of T cell-mediated immune responses of mice.

Authors:  S Kai; J Tanaka; K Nomoto; M Torisu
Journal:  Clin Exp Immunol       Date:  1979-07       Impact factor: 4.330

10.  Postoperative chemotherapy including intraperitoneal and intradermal administration of the streptococcal preparation OK-432 for patients with gastric cancer and peritoneal dissemination: a prospective randomized study.

Authors:  K Sugimachi; Y Maehara; K Akazawa; Y Kondo; Y Kunii; M Kitamura; H Yamaoka; Y Takahashi; T Kito; M Katou
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.